CELU
Celularity
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CELU
Celularity Inc.
A clinical stage biopharmaceutical company that develops placenta-derived allogeneic cell therapies for cancer, infectious and degenerative diseases
Biological Technology
08/29/2016
08/08/2019
NASDAQ Stock Exchange
120
12-31
Common stock
170 Park Ave, Florham Park, NJ 07932
--
Celularity Inc. was incorporated under the laws of the State of Delaware on August 29, 2016. Cellarity is a clinical-stage biotechnology company that is leading the next development direction of cell medicine by developing off-the-shelf placenta-derived allogeneic T cells, utilizing chimeric antigen receptor cells, natural killer cells (" NK ") cells and mesenchymal adhesion stromal cells (" ASCs ") for cancer, infectious and degenerative diseases. Cellarity believes that by leveraging the unique biology and ready availability of the placenta, it will be able to develop therapeutic solutions to meet the significant global demand for effective, accessible and affordable treatments.
Company Financials
EPS
CELU has released its 2023 Q3 earnings. EPS was reported at -0.50, versus the expected -0.03, missing expectations. The chart below visualizes how CELU has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CELU has released its 2024 Q3 earnings report, with revenue of 9.30M, reflecting a YoY change of 145.54%, and net profit of -16.10M, showing a YoY change of 82.85%. The Sankey diagram below clearly presents CELU’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
